Clinical Trials Logo

Clinical Trial Summary

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
  • Advanced Solid Tumors With FGFR1 Amplication
  • Advanced Solid Tumors With FGFR2 Amplication
  • Advanced Solid Tumors With FGFR3 Mutation
  • Bladder Cancer With FGFR3 Mutation or Fusion
  • Neoplasms
  • Squamous Lung Cancer With FGFR1 Amplification
  • Urinary Bladder Neoplasms

NCT number NCT01004224
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 1
Start date December 11, 2009
Completion date October 8, 2018